Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK) announced CEO Taylor Schreiber, M.D., Ph.D., will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:10 AM ET in Boston and hold one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference March 10-11 in Miami.

Live audio webcasts will be available via the company's Investor Relations website, with replay accessible for about 30 days after each presentation.

News Market Reaction – STTK

-5.37%

5 alerts

-5.37% Session close to close

$258.18M Market Cap

1.1x Rel. Volume

In the Feb 25 session, STTK declined 5.37%, reflecting a notable negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.4% in the session following this news. A negative reaction despite neutral confer...

Analysis

The stock moved -5.4% in the session following this news. A negative reaction despite neutral conference news would fit a backdrop where financing tools are active. The company has an effective shelf of up to $200,000,000 and a $75,000,000 ATM program, alongside prior insider Form 4 dispositions. Historically, news around governance, inducement grants, or capital access has produced only modest moves, so any pronounced decline would have contrasted with those typically measured reactions.

Key Figures

ATM program size: $75,000,000 ATM commission: 3.0% Last reported price: $4.44 +5 more

8 metrics

ATM program size $75,000,000 At-the-market stock offering program with Leerink Partners (424B5, Jan 22, 2026)

ATM commission 3.0% Maximum sales agent commission on gross sales under ATM program

Last reported price $4.44 Nasdaq STTK last reported sale on January 21, 2026 (424B5)

Shelf capacity $200,000,000 Aggregate offering amount under Form S-3 shelf registration filed Jan 13, 2026

13G ownership 7,373,891 shares (11.7%) T. Rowe Price Investment Management, Inc. beneficial ownership (Schedule 13G)

Officer stock option 351,400 shares at $4.75 Option grant to Stephen Stout on January 10, 2026 (Form 4)

Cash & investments $86.1M Cash and short-term investments at Q3 2025 earnings update

Private placement $103 million August 2025 private placement; proceeds expected to fund operations into 2029

Historical Context

5 past events · Latest: Feb 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 06	Investor symposium	Neutral	+5.6%	Piper Sandler immunology symposium fireside chat and replay availability.
Dec 15	Inducement grants	Negative	-3.9%	Inducement stock options for new hire under Nasdaq Listing Rule 5635(c)(4).
Nov 20	Investor conferences	Neutral	-1.5%	December 2025 participation in multiple healthcare investor conferences.
Nov 06	Earnings & funding	Positive	+1.0%	Q3 2025 results, SL-325 IND clearance, dosing start, and up to $103M placement.
Oct 02	KOL panel	Neutral	-0.4%	Planned participation in Wedbush-hosted KOL and company panel post-UEGW.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has mostly involved investor events, governance, and financing; price reactions around these items have been modest and generally aligned with the nature of the announcements.

Recent Company History

Over the past several months, Shattuck has regularly communicated corporate milestones and outreach. Investor and KOL events in October 2025, November 2025, and February 2026 were paired with small share-price moves. The Q3 2025 update highlighted IND clearance for SL-325, initial dosing, and funding of up to $103M, extending runway into 2029. Today’s March conference participation continues this pattern of investor-facing visibility rather than a new clinical or financial inflection.

Key Terms

monoclonal, bispecific, DR3-blocking antibodies

3 terms

monoclonal medical

"pioneering the development of potentially first-in-class monoclonal and bispecific"

Monoclonal describes a therapeutic product or laboratory reagent made from a single original cell, so every molecule or antibody in the batch is virtually identical. Investors care because that uniformity usually means predictable behavior, easier quality control, clearer regulatory approval paths and stronger intellectual property; think of it like manufacturing identical keys rather than cutting many different ones by hand, which reduces surprises and supports reliable production and pricing.

bispecific medical

"development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies"

A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

DR3-blocking antibodies medical

"bispecific DR3-blocking antibodies for the treatment of patients with inflammatory"

DR3-blocking antibodies are engineered proteins that stick to the cell-surface receptor called DR3 and prevent that receptor from being activated. Think of them as caps placed over a lock so the normal key can’t turn it; by stopping DR3’s signals they can dial down certain immune reactions such as inflammation or autoimmune attack. Investors care because success or failure of these molecules in trials influences drug pipelines, potential market opportunities, development risk and future revenue for companies working in immune-related conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

Conference Details

TD Cowen 46^th Annual Health Care Conference

Format: Corporate presentation and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Presentation Date: March 2, 2026
Time: 9:10 AM ET
Location: Boston, MA
Webcast link: HERE

Leerink Partners 2026 Global Health Care Conference

Format: One-on-one investor meetings
Participant: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Dates: March 10-11, 2026
Location: Miami, FL

Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.shattucklabs.com. Replay webcasts will be available for approximately 30 days following the live presentations.

About SL-325
SL-325 is a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK), a clinical-stage biotechnology company, is pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. The Company’s expertise in protein engineering and the development of novel TNF receptor therapeutics comes together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

When will Shattuck Labs (STTK) present at the TD Cowen 46th Annual Health Care Conference?

Shattuck Labs will present on March 2, 2026 at 9:10 AM ET. According to the company, CEO Taylor Schreiber will give a corporate presentation and participate in one-on-one meetings in Boston, and the session will be available via live audio webcast on the investor site.

How can investors access the Shattuck Labs (STTK) conference webcasts and replays?

Investors can access live audio webcasts via the company's Investor Relations website at www.shattucklabs.com. According to the company, replay webcasts will be available for approximately 30 days following each live presentation for later review.

Who will represent Shattuck Labs (STTK) at the March 2026 investor conferences?

CEO Taylor Schreiber, M.D., Ph.D., will represent Shattuck Labs at both events. According to the company, he will present at TD Cowen and hold one-on-one investor meetings at the Leerink Partners conference.

What is the format of Shattuck Labs (STTK) participation at the Leerink Partners 2026 Global Health Care Conference?

Shattuck Labs will participate in one-on-one investor meetings on March 10–11, 2026. According to the company, these meetings in Miami will be investor-focused rather than public presentations and are scheduled as individual meetings with management.

Will Shattuck Labs (STTK) provide a replay of the March 2, 2026 presentation and for how long?

Yes, a replay will be provided and accessible for about 30 days after the live presentation. According to the company, replay webcasts of the March 2 session will be posted on the Investor Relations section of the company website for that period.